Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
Immune status of blood product recipients.
JAMA. 1985 Feb 22;253(8):1140-5. Unique Identifier : AIDSLINE MED/85108350 Jason J; Hilgartner M; Holman RC; Dixon G; Spira TJ; Aledort L; Evatt B
Abstract:
Persons with hemophilia are at risk of the acquired immunodeficiency syndrome (AIDS), and clinically asymptomatic hemophiliacs have shown a high incidence of AIDS-like immune abnormalities, facts leading to speculation that many hemophiliacs have been exposed to the AIDS agent through their blood products. We therefore evaluated the immune status of three groups of blood product recipients without AIDS in New York City, including 47 persons with hemophilia A receiving factor VIII concentrate, 50 persons with homozygous beta-thalassemia, and 27 persons with sickle cell anemia receiving frozen-packed RBCs and 20 healthy persons who had not received a transfusion. Hemophiliac participants had significantly lower lymphocyte counts (median, 1,826/cu mm) than did the thalassemic (6,110/cu mm) or anemic (4,443/cu mm) participants, had lower numbers of T-helper lymphocytes (median, 533 cells/cu mm v 1,733 cells/cu mm and 1,554 cells/cu mm), and had a lower T-helper/suppressor ratio (median, 0.8 v 1.8 and 2.1). These differences remained after adjustment for age and sex. Thus, AIDS-like immune abnormalities were found in patients receiving factor concentrate, but not in those receiving RBCs. These defects could be due to both an immunosuppressive effect of the lyophilized factor itself and to contact with the AIDS agent.
Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY/TRANSMISSION Adolescence Adult Anemia, Sickle Cell/*IMMUNOLOGY/THERAPY Blood Transfusion/*ADVERSE EFFECTS Child Comparative Study Erythrocytes/TRANSPLANTATION Factor VIII/ADMINISTRATION & DOSAGE/*ADVERSE EFFECTS Female Hemophilia/*IMMUNOLOGY/THERAPY Human Immunoglobulins/ANALYSIS Leukocyte Count Lymphocytes/CLASSIFICATION Male Middle Age Splenectomy Support, U.S. Gov't, P.H.S. Thalassemia/*IMMUNOLOGY/THERAPY JOURNAL ARTICLE
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
